METTL3 and breast cancer: Ni et al. (Ni et al., 2022) reported that activated JNK signaling is associated with increased METTL3 expression in BC, and inhibition of JNK signaling reduced the expression of METTL3 and Programmed death ligand 1 (PD-L1).